SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Needham Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $40

Needham analyst Alan Carr initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $40.

Benzinga · -
Needham analyst Alan Carr initiates coverage on Pliant Therapeutics (NASDAQ: PLRX) with a Buy rating and announces Price Target of $40.